a 2nd randomzed managed phase study, oneear OS rates had been 93% and 91% patents assgned to lenaldomde plushgh dose dexamethasone andhgh dose dexamethasone alone, respectvely.83 a subgrouanalyss that consdered patents wth and wthout abnormal karyotypes at baselne, oneear OS rates amongst people wth abnormal karyotypes had been 82% and 77% patents taken care of wth lenaldomde plushgh dose dexamethasone and dexamethasone alone, respectvely.91 Among a cohort of 34 patents taken care of wth lenaldomde plus dexamethasone a phase review, two and threeear OS was approxmately 91% and 88%, respectvely.43 RMAmong 53 elderly patents handled wth RMa phase review, the oneear OS fee was 100%.41 Amongst 21 patents treated wth the maxmum tolerated dose ths research followed by lenaldomde 10 mg day o21 of each 28 days as mantenance treatment, the twoear OS fee was 90.
5%.92 Adverse occasions Lenaldomde plus dexamethasone A phase research conducted from the EasterCooperatve Oncology Groureported a decrease charge of grade recommended reading 3 or 4 adverse events among patents who had been random zed to lenaldomde plus lower dose dexamethasone thapatents randomzed to lenaldomde plushgh dose dexamethasone.90 patents assgned tohgh versus minimal dose dexamethasone, major grade 3 or 4 toxctes and ther respectve rates were neutropena, VTE, and nfectopneumona.Grade three or four nonhematologcal toxctes occurred 49% and 32% of patents assgned tohgh versus very low dose dexamethasone, respectvely combnatowth lenaldomde.Of verfed deaths thehgh dose dexamethasone arm, 13 had been thanks to dsease progresson, sx situations have been related to VTE, three have been as a result of nfecton, and one other fve circumstances were because of cardac schema, stroke, and respratory faure.
Of nne verfed deaths the very low dose dexamethasone arm, fve had been because of dsease progresson, two to nfecton, one particular to VTE, and one to cardac arrest.the frst four months of therapy, the kinase inhibitor Roscovitine mortalty rate was 5% thehgh dose dexamethasone groucompared wth 0.5% the very low dose group.a 2nd randomzed, double blnd, phase study, lenaldomde plushgh dose dexamethasone was assocated wth ahgher charge of adverse occasions thatreatment wthhgh dose dexamethasone alone.83 Grade 3 or four neutropena was reported by 13.5% of patents treated wth lenaldo mde plushgh dose dexamethasone in contrast wth two.4% of patents handled wthhgh dose dexamethasone alone.There were 20 VTE occasions the lenaldomde plus dexamethasone grouncludng 14 events assocated wth asprprophylaxs, there were twelve thromboembolc events the dexamethasone only grouall of whch had been assocated wth asprprophylaxs.
phase studes of lenaldomde plus dexamethasone, 47% 55% of patents experenced a grade three or four nonhema tologcal toxcty durng treatment, most often fatgue, anxety, pneumonts, muscle weakness, and rash.42,43 Grade 3 or 4hemato logcal adverse occasions ncluded neutropena, leucopena, lymphopena,

and anema.